SYNCOMF
Syncom Formulations (India) Limited (SYNCOMF) Stock Analysis
Syncom Formulations (India) Limited is an Indian pharmaceutical formulations company manufacturing tablets, capsules, liquids, and other dosage forms. It supplies generic and branded medicines across therapeutic segments to domestic and export markets. The company operates WHO-GMP compliant facilities and serves institutional and retail channels. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹23.30
-2.84% 1W | +38.70% 52W
Market Cap
2.2k CR
P/E Ratio
24.8
52W High
₹27.5
52W Low
₹10.2
Div. Yield
0.42%
Beta
0.8
50 DMA
₹18.7
200 DMA
₹14.7
Profit Margin
17.2%
Inst. Own.
0.1%
📊 ANALYZING TREND
🚀 BREAKOUT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60 | 64 | 65 | 75 | 87 | 102 | 128 | 149 | 117 | 122 | 115 | 135 | 126 |
| Expenses | 53 | 57 | 58 | 65 | 77 | 90 | 113 | 131 | 101 | 103 | 94 | 113 | 99 |
| Operating Profit | 6 | 6 | 7 | 9 | 10 | 12 | 15 | 18 | 16 | 18 | 21 | 22 | 26 |
| OPM % | 11% | 10% | 11% | 13% | 12% | 12% | 12% | 12% | 14% | 15% | 18% | 16% | 21% |
| Other Income | 2 | 4 | 5 | 3 | 1 | 4 | 4 | 7 | 6 | 5 | 6 | 15 | 8 |
| Interest | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | 6 | 8 | 9 | 10 | 10 | 15 | 17 | 23 | 20 | 22 | 25 | 34 | 32 |
| Tax % | 28% | 23% | 25% | 26% | 24% | 25% | 25% | 24% | 22% | 25% | 25% | 25% | 23% |
| Net Profit | 4 | 7 | 7 | 7 | 8 | 11 | 13 | 18 | 16 | 17 | 19 | 25 | 25 |
| EPS in Rs | 0.05 | 0.07 | 0.07 | 0.08 | 0.08 | 0.12 | 0.14 | 0.19 | 0.17 | 0.18 | 0.20 | 0.27 | 0.26 |
| Metric | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 115 | 151 | 173 | 184 | 185 | 216 | 222 | 262 | 463 | 488 | 498 |
| Expenses | 104 | 135 | 155 | 167 | 168 | 196 | 202 | 232 | 408 | 411 | 410 |
| Operating Profit | 11 | 16 | 18 | 17 | 17 | 20 | 20 | 30 | 54 | 77 | 88 |
| OPM % | 9% | 11% | 11% | 9% | 9% | 9% | 9% | 11% | 12% | 16% | 18% |
| Other Income | 1 | 1 | 1 | 3 | 3 | 12 | 15 | 14 | 17 | 31 | 33 |
| Interest | 1 | 0 | 0 | 0 | 0 | 2 | 3 | 5 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 4 | 5 | 5 | 5 | 7 | 7 |
| Profit before tax | 8 | 14 | 16 | 16 | 16 | 26 | 27 | 34 | 66 | 101 | 113 |
| Tax % | 33% | 33% | 38% | 36% | 34% | 24% | 24% | 25% | 25% | 24% | |
| Net Profit | 6 | 9 | 10 | 10 | 11 | 20 | 20 | 25 | 49 | 76 | 86 |
| EPS in Rs | 0.07 | 0.12 | 0.13 | 0.13 | 0.13 | 0.23 | 0.21 | 0.27 | 0.53 | 0.81 | 0.91 |
| Dividend Payout % | 24% | 17% | 16% | 15% | 15% | 13% | 0% | 0% | 0% | 12% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 30.0% | – | 10.0% |
| Profit CAGR | 50.0% | – | 20.0% |
Shareholding Pattern
Promoters50.57%
FIIs0.41%
Public49.02%
Promoters50.57%
FIIs0.10%
Public49.33%
Promoters50.57%
FIIs0.26%
Public49.17%
Promoters50.57%
FIIs0.21%
Public49.23%
Promoters50.57%
FIIs0.35%
Public49.07%
Promoters50.57%
Public49.44%
Promoters50.57%
FIIs0.08%
Public49.35%
Promoters50.57%
FIIs0.11%
Public49.32%
Promoters50.57%
FIIs0.21%
Public49.23%
Promoters50.57%
FIIs0.35%
Public49.07%
SYNCOMF
Holdings Analysis
Key strengths & risk signals
84
Overall
74
Fundamental
94
Technical
Risks (1)
TOO MUCH PUBLIC HOLDING! 49.44% public ownership - higher volatility risk.
Strengths (4)
UNDERVALUED! PEG of 0.44 indicates stock is cheap relative to growth.
BULLISH TREND! 50-day average (18.7) is above 200-day average (14.7) - positive signal.
BREAKOUT! Stock has broken above resistance levels with momentum.
GOOD YEAR! Stock gained 38.7% in the last year.
Fundamental & Technical Analysis
84Overall
74Fundamental
94Technical
Fundamental Breakdown
Growth Quality
30/30
Revenue CAGR: 29.4% (EXCELLENT, 15/15). Profit CAGR: 56.2% (EXCELLENT, 15/15).
Profit Margin
6/10
GOOD EFFICIENCY! 17.2% profit margin - above average profitability.
PEG Valuation
10/10
UNDERVALUED! PEG of 0.44 indicates stock is cheap relative to growth.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.42% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 49.44% public ownership - higher volatility risk.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (18.7) is above 200-day average (14.7) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (23.3) is above both moving averages.
Trend Pattern
20/20
BREAKOUT! Stock has broken above resistance levels with momentum.
52W Performance
10/10
GOOD YEAR! Stock gained 38.7% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 35,534,259 vs down days: 20,584,990. Ratio: 1.73x
RSI
3/5
NEUTRAL! RSI at 59.1 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 75.7% of 52W range - positive territory.
Momentum
3/5
MIXED MOMENTUM! Price growth is inconsistent - -2.8% (1 week), 15.6% (1 month), 64.2% (3 months).
Beta
4/5
BELOW MARKET! Beta of 0.80 - slightly less volatile than market.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SYNCOMF | ₹23.30 | 24.8 | 17.2% | 29.4% | 56.2% | +38.7% | 84 | BREAKOUT | +57.0% | -1.6% | +7.4% | -7.3% |
| SAKAR | ₹1,011.50 | 72.3 | 13.3% | 22.0% | 23.0% | +184.6% | 78 | BREAKDOWN | +112.8% | -9.1% | +38.5% | +2.7% |
| VENUSREM | ₹1,719.50 | 22.4 | 13.4% | 11.6% | 57.0% | +264.9% | 74 | BREAKDOWN | +126.2% | +85.5% | +31.2% | +43.9% |
| INDOCO | ₹230.70 | 699.1 | 0.3% | 3.0% | – | -14.2% | 54 | BREAKDOWN | -281.6% | -400.9% | +8.2% | +2.3% |
| WINDLAS | ₹949.20 | 30.4 | 7.1% | 20.7% | 16.0% | +11.7% | 75 | BREAKDOWN | 0.0% | +10.6% | +18.1% | +4.0% |
| BETA | ₹1,950.20 | 28.7 | 11.1% | 19.2% | 10.5% | +13.7% | 67 | APPROACHING SUPPORT | +35.0% | +75.6% | +25.2% | +33.5% |
| HESTERBIO | ₹2,058.70 | 12.8 | 41.6% | 7.7% | 27.8% | +24.4% | 76 | BOUNCE FROM SUPPORT | +491.5% | +506.3% | -8.2% | -22.9% |
| HIKAL | ₹213.70 | – | -1.9% | -5.4% | – | -9.2% | 52 | CONSOLIDATING DOWN | -67.0% | -151.4% | +7.7% | -22.7% |
Data from TradeAlone · Updated daily
No news tagged for SYNCOMF yet.
